Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Rebello, M. Mangale, S. Chachad, G. Malhotra, S. Purandare, S. Salvi, B. Brashier, A. Mesquita, L. Fernandes, G. D‘Souza (Mumbai, Pune, Panaji, Banglore, India). Comparison of the bronchoprotective effects of two salbutamol suplphate HFA pMDI using methacholine challenge testing. Eur Respir J 2011; 38: Suppl. 55, 3980

Member's Comments

No comment yet.

Related content which might interest you: Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler(R) DPI Source: Eur Respir J 2003; 21: 816-820 Year: 2003 Reliever effect of extrafine BDP/F DPI in asthmatic patients after methacholine challenge Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003 Bronchodilating effects of fenoterol CFC and fenoterol HFA Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001 Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003 Comparison of bronchodilator effect of salbutamol delivered via MDI + spacer and DPI in children with asthma Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012 COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Attenuation of exercise-induced bronchoconstriction with montelukast or salmeterol added to inhaled fluticasone in children Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005 Comparative evaluation of formoterol budesonide combination MDI and salbutamol MDI for reversibility testing in patients with obstructive airways disease Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 209s Year: 2006 Nebulized salbutamol through the ultrasonic nebulizer during sputum induction improves the bronchoprotection in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002 Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB) Source: Eur Respir J 2002; 20: Suppl. 38, 306s Year: 2002 Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007 A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005